Cesca Therapeutics Inc. to Participate in the LD Micro 10th Annual Main Event on Thursday, December 7, 2017
November 30 2017 - 7:30AM
Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) a market leader in
automated cell processing and point-of-care, autologous cell-based
therapies, today announced that Joe Balagot, senior vice president
of corporate development, will be presenting at the LD Micro 10th
Annual Main Event on Thursday, December 7 at 8:30am PST. The
conference is being held December 5 – 7, 2017 at the Luxe Sunset
Boulevard Hotel in Los Angeles.
A live webcast of the presentation will be
available at http://wsw.com/webcast/ldmicro13/kool. The webcast
will be archived for 90 days.
About Cesca Therapeutics
Inc. Cesca
is a leading regenerative medicine company that develops,
commercializes and markets a range of automated technologies for
cell-based therapeutics. Its device division, ThermoGenesis,
provides a full suite of solutions for automated clinical
biobanking, point-of-care applications, and automation for
immuno-oncology. Cesca is also leveraging its proprietary
AutoXpress® technology platform to develop an automated,
functionally-closed CAR-TXpress platform that addresses cellular
manufacturing needs in the immuno-oncology field.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Cesca’s current
expectations concerning future events and results. Forward-looking
statements based on Cesca’s current assumptions, expectations and
beliefs are generally identifiable by use of words “may,” “might,”
“will,” “should,” “expects,” “plans,” “anticipates,” “believes,”
“estimates,” “predicts,” “potential” or “continue,” or similar
expressions and involve significant risks and uncertainties that
could cause actual results, developments and business decisions to
differ materially from those contemplated by these statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those risk factors discussed in Item 1A of our most
recent Annual Report on Form 10-K filed with the Securities and
Exchange Commission (“SEC”) as well as other documents that may be
filed by Cesca from time to time with the SEC, which are available
at www.sec.gov. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Company Contact: Cesca Therapeutics Inc. Wendy
Samford916-858-5191ir@cescatherapeutics.com
Investor Contact: Rx CommunicationsPaula
Schwartz917-322-2216pschwartz@rxir.com
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Apr 2023 to Apr 2024